文献速递神经免疫

多发性硬化初始高效DMT全国队列研究

Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
PubMed 文献 · Neurology · 2020-07-07

基于丹麦多发性硬化登记研究,纳入388例初治患者,194例起始高效DMT与194例倾向评分匹配的中效DMT比较。4年随访显示高效DMT组6个月确认EDSS恶化概率16.7% vs 30.1%(HR 0.53,95%CI 0.33-0.83,p=0.006),首次复发风险也更低(HR 0.50,95%CI 0.37-0.67)。

要点

  • 初治即用高效DMT可降低4年确认残疾进展风险(HR 0.53)
  • 高效DMT组首次复发风险显著低于中效DMT组(HR 0.50)
  • 高基线活动等亚组结果一致,支持早期高效治疗策略

核心结论

  • 初治即用高效DMT较中效DMT降低6个月确认EDSS恶化及首次复发概率。

研究设计与样本

  • 基于丹麦多发性硬化登记研究的全国人群队列,纳入388例初治患者,194例高效DMT与194例倾向评分匹配的中效DMT比较。

主要发现

  • 4年随访6个月确认EDSS恶化概率高效DMT组16.7%(95%CI 10.4%-23.0%),中效DMT组30.1%(95%CI 23.1%-37.1%),HR 0.53(95%CI 0.33-0.83,p=0.006)。
  • 高效DMT组首次复发风险更低,HR 0.50(95%CI 0.37-0.67)。
  • 成对删失及高基线活动、2006年后诊断、有基线T2病灶负荷信息亚组结果相似。

临床怎么用

  • 对初治MS患者,可考虑起始高效DMT以降低残疾进展和复发风险。

局限性

  • 研究为观察性队列,证据等级为Class III。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effectiveness of high-efficacy disease-modifying therapies (heDMTs) vs medium-efficacy disease-modifying therapies (meDMT) as the first treatment choice in treatment-naive patients with multiple sclerosis (MS) on disability worsening and relapses. We assessed this using a nationwide population-based MS registry. METHODS: We identified all patients starting a heDMT as first-time treatment from the Danish Multiple Sclerosis Registry and compared treatment outcomes with a propensity score matched sample of patients starting meDMT. RESULTS: We included 388 patients in the study: 194 starting initial therapy with heDMT matched to 194 patients starting meDMT. At 4 years of follow-up, the probabilities of a 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening were 16.7% (95% confidence interval [CI] 10.4%-23.0%) and 30.1% (95% CI 23.1%-37.1%) for heDMT and meDMT initiators, respectively (hazard ratio [HR] 0.53, 95% CI 0.33-0.83, p = 0.006). Patients initiating heDMT also had a lower probability of a first relapse (HR 0.50, 95% CI 0.37-0.67). Results were similar after pairwise censoring and in subgroups with high baseline activity, diagnosis after 2006, or information on baseline T2 lesion load. CONCLUSION: We found a lower probability of 6-month confirmed EDSS score worsening and lower probability of a first relapse in patients starting a heDMT as first therapy, compared to a matched sample starting meDMT. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with MS, starting heDMT lowers the risk of EDSS worsening and relapses compared to starting meDMT.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. Neurology. 2020. PMID: 32636328. doi:10.1212/WNL.0000000000010135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。